Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $25.2 million.

  • Theravance Biopharma's Other Non-Current Assets rose 23736.44% to $25.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.2 million, marking a year-over-year increase of 23736.44%. This contributed to the annual value of $12.3 million for FY2024, which is 5229.95% up from last year.
  • Theravance Biopharma's Other Non-Current Assets amounted to $25.2 million in Q3 2025, which was up 23736.44% from $25.8 million recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Other Non-Current Assets peaked at $25.8 million during Q2 2025, and registered a low of $1.3 million during Q2 2021.
  • Its 5-year average for Other Non-Current Assets is $9.0 million, with a median of $7.7 million in 2024.
  • Per our database at Business Quant, Theravance Biopharma's Other Non-Current Assets surged by 29579.83% in 2021 and then plummeted by 3470.6% in 2024.
  • Theravance Biopharma's Other Non-Current Assets (Quarter) stood at $3.2 million in 2021, then surged by 113.72% to $6.9 million in 2022, then increased by 16.93% to $8.1 million in 2023, then skyrocketed by 52.3% to $12.3 million in 2024, then surged by 105.04% to $25.2 million in 2025.
  • Its Other Non-Current Assets stands at $25.2 million for Q3 2025, versus $25.8 million for Q2 2025 and $13.8 million for Q1 2025.